Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, Luukkaa M, Nyandoto P, Hemminki A, Nilsson S, McCaffrey J, Asola R, Turpeenniemi-Hujanen T, Laestadius F, Tasmuth T, Sandberg K, Keane M, Lehtinen I, Luukkaala T, Joensuu H; PROSTY study group. Kellokumpu-Lehtinen PL, et al. Among authors: harmenberg u. Lancet Oncol. 2013 Feb;14(2):117-24. doi: 10.1016/S1470-2045(12)70537-5. Epub 2013 Jan 4. Lancet Oncol. 2013. PMID: 23294853 Clinical Trial.
Curative radiation therapy in prostate cancer.
Harmenberg U, Hamdy FC, Widmark A, Lennernäs B, Nilsson S. Harmenberg U, et al. Acta Oncol. 2011 Jun;50 Suppl 1:98-103. doi: 10.3109/0284186X.2010.576115. Acta Oncol. 2011. PMID: 21604948
Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.
Cortés-González JR, Castellanos E, Sandberg K, Eriksson MH, Wiklund P, Carlsson S, Cohn-Cedermark G, Harmenberg U, Gustafsson O, Levitt SH, Lennernäs B, Brandberg Y, Márquez M, Kälkner KM, Nilsson S. Cortés-González JR, et al. Among authors: harmenberg u. Int J Oncol. 2013 Jan;42(1):109-17. doi: 10.3892/ijo.2012.1694. Epub 2012 Nov 13. Int J Oncol. 2013. PMID: 23151842 Clinical Trial.
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ. Escudier B, et al. Among authors: harmenberg u. J Clin Oncol. 2009 Sep 1;27(25):4068-75. doi: 10.1200/JCO.2008.20.5476. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652072 Clinical Trial.
An expression signature at diagnosis to estimate prostate cancer patients' overall survival.
Peng Z, Skoog L, Hellborg H, Jonstam G, Wingmo IL, Hjälm-Eriksson M, Harmenberg U, Cedermark GC, Andersson K, Ahrlund-Richter L, Pramana S, Pawitan Y, Nistér M, Nilsson S, Li C. Peng Z, et al. Among authors: harmenberg u. Prostate Cancer Prostatic Dis. 2014 Mar;17(1):81-90. doi: 10.1038/pcan.2013.57. Epub 2014 Jan 7. Prostate Cancer Prostatic Dis. 2014. PMID: 24394557 Free PMC article.
55 results